Skip to main content
News and Products

Volpara expands relationship with GE Healthcare

Volpara Solutions have announced the launch of an expanded agreement enabling the worldwide distribution of its industry-leading VolparaDensity software by GE Healthcare. Now installed in more than 35 countries, the VolparaDensity clinical application analyses mammograms using machine learning to provide radiologists with automated, objective, and volumetric breast density assessments and a breast density category that has been shown to correlate to BI-RADS 4th and 5th Editions. With more than 100 peer-reviewed papers and more than 250 publications, VolparaDensity is the most clinically validated breast density assessment software in the world. Having an objective and validated measure of breast density allows providers to deliver personalized breast care to their patients by easily identifying women with dense breasts. Such women have an increased risk of developing breast cancer and are also at a greater risk of having a cancer go undetected using conventional 2D and 3D mammography. Since both dense breast tissue and tumor lesions can appear white on a mammogram, women with dense breasts may benefit from additional screening such as that delivered by the GE Invenia Automated Breast Ultrasound (ABUS) which has been shown to find small, invasive cancers missed by mammography, particularly in dense breasts.

We are excited to expand access to VolparaDensity as part of our product portfolio,” stated Luke Delaney, General Manager of Automated Breast Ultrasound at GE Healthcare. “Now, our customers outside the US will also have access to a proven technology that will help them identify women who may benefit from a supplemental screening modality, such as the Invenia ABUS system. ” Dr. J P Russo, Section Chief of Women’s Imaging at St. Luke’s University Health Network in Bethlehem, PA, said: “There are still certain signs of breast cancer that are best seen on a mammogram, which is why the Invenia ABUS is used in addition to mammography. ABUS screening helps find cancers obscured by dense tissue. Accurate density measurements and quality imaging are very important in breast cancer detection. I encourage women to learn their breast density, understand the risk, and talk to their healthcare providers to get the personalized healthcare they need.

Volpara Solutions

Wellington,New Zealand